December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Mark Lewis: RAS(ON) inhibitor responses in pancreatic adenocarcinoma
Sep 18, 2024, 12:30

Mark Lewis: RAS(ON) inhibitor responses in pancreatic adenocarcinoma

Mark Lewis posted the following on X:

“Per Ignacio Garrido-Laguna, RMC-6236, a RAS(ON) multiselective inhibitor, can induce responses across a variety of KRAS mutations even in heavily pretreated patients with pancreatic adenocarcinoma!”

Mark Lewis: RAS(ON) inhibitor responses in pancreatic adenocarcinoma

Source: Mark Lewis/X

Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer. His interests are neuroendocrine tumors and cancer syndromes.